Adam Townsend

Adam Townsend has extensive experience in the biotechnology and pharmaceutical industries, currently serving as Chief Executive Officer at Merida Biosciences since March 2025. Prior roles include Chief Operating Officer and Chief Commercial Officer at Apellis Pharmaceuticals from November 2018 to March 2025. Adam’s tenure at Biogen spanned eight years, during which various senior leadership positions were held, including Senior Vice President of Corporate Development and Senior Vice President for the Specialty Medicines and Rare Disease Group. Additional experience includes key marketing and managerial roles at EUSA Pharma and Amgen, and starting a career as a Specialist Representative at Novartis. Adam Townsend earned a degree from the Royal Holloway, University of London between 1994 and 1997.